Amplia Therapeutics Limited is founded in 2016, operates from its headquarter in Level 17, 350 Queen Street Melbourne, Victoria 3000, AU. The company operates in the Manufacturing, Pharmaceuticals sector.
Amplia Therapeutics Limited specializes in Focal Adhesion Kinase (FAK) inhibition, Cancer therapy development, Fibrosis treatment, Immuno-oncology drug development, Multi-action molecule development, and offers services including FAK inhibitors, AMP945, and AMP886.